BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS (KRAS mutated in ~40% of CRCs) or RAF (BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13,14,15].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For cancers with activating BRAF mutations, various BRAF inhibitors are now available, such as vemurafenib, dabrafenib, and encorafenib, that selectively and competitively inhibit mutant BRAF and interfere with downstream MAPK signaling [14].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“BRAF mutation in mCRC carries independent prognostic value and significant associations with clinical and biological disease characteristics [6].”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 1×
“In vitro, sensitivity to HGF or c-MET inhibition was observed, suggesting c-MET could be another therapeutic target [64].”
BackgroundCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
A Big Bang model of human colorectal tumor growth
Sottoriva, A., Kang, H., Ma, Z., Graham, T. A., Salomon, M. P., Zhao, J., Marjoram, P., Siegmund, K., Press, M. F., Shibata, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3214 · Cited by 1,015
Diaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00197-8 · Cited by 945
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592 · cited 1×
“All patients with PI3K mutations responded to treatment [62].”
BackgroundTabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569 · cited 2×
“In the aforementioned BEACON study [39], an attempt was made to establish a correlation between the clinical outcomes and molecular findings in tumor samples.”
BackgroundMethodTumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562 · cited 1×
“However, class III mutations require a second hit to be oncogenic, such as KRAS mutation, NRAS mutation, or EGFR receptor activation [12].”
BackgroundRichman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 1×
“In cell populations developing resistance to EGFRi, an activation of the MAPK pathway through alternative receptor tyrosine kinases (RTKs) like Her2 or MET was observed [48].”
BackgroundPietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · cited 1×
“However, a meta-analysis concluded that EGFR blockade does not enhance the efficacy of standard chemotherapy in BRAF -mutated mCRC [26,27].”
BackgroundSullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Maru, D., Yan, Y., Lanman, R., Manyam, G., Hong, D. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 389
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317 · cited 1×
“An average overall survival of 13.5 months was observed compared to 30.6 months in the BRAF wild-type patients ( p = 0.001) [16].”
ResultInfluentialIncreased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309
Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290 · cited 1×
“In CCR cell samples, PI3K is more activated compared to melanoma cells [61], leading to hypotheses of whether PI3K could be inhibited to bypass BRAFi resistance.”
BackgroundEmergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271
Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Del Monte, F., Cortesi, E., Amoroso, D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70175-3 · Cited by 239
Cremolini, C., Antoniotti, C., Stein, A., Bendell, J., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 235
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232 · cited 1×
“A comparison between encorafenib + cetuximab and the same doublet with the addition of a PI3K inhibitor (PI3Ki), alpelisib, showed few differences in outcomes: ORR of 29% and 18%, respectively; median PFS of 3.7 months or 4.2 months, respectively, with more toxicity in the alpelisib group [63].”
BackgroundInfluentialHong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Delord, J.-P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2923 · Cited by 198
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J., Burke, K., Jorgji, V., Sindurakar, P., Braverman, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02181-8 · Cited by 198
Seligmann, J. F., Fisher, D., Smith, C. G., Richman, S. D., Elliott, F., Brown, S., Adams, R., Maughan, T., Quirke, P., Cheadle, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw645 · Cited by 165
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
Caputo, F., Santini, C., Bardasi, C., Cerma, K., Casadei-Gardini, A., Spallanzani, A., Andrikou, K., Cascinu, S., & Gelsomino, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215369 · Cited by 162
Mar, V., Wong, S. Q., Li, J., Scolyer, R. A., McLean, C., Papenfuss, A. T., Tothill, R. W., Kakavand, H., Mann, G. J., Thompson, J. F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0398 · Cited by 152
BRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer
Barras, D. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25248 · Cited by 138 · cited 2×
“Apart from its role in the MAPK pathway, BRAF is involved in other cellular processes, like migration (via RHO small GTPases), apoptosis (via BCL-2 regulation), and survival (via the HIPPO pathway) [7].”
BackgroundResponse to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Van Seventer, E. E., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 125
BRAF inhibitors in cancer therapy
Johansson, C. H., & Brage, S. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.011 · Cited by 122
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Elez, E., Ros, J., Fernández, J., Villacampa, G., Moreno-Cárdenas, A. B., Arenillas, C., Bernatowicz, K., Comas, R., Li, S., Kodack, D. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01976-z · Cited by 111
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103 · cited 1×
“In fact, there are studies demonstrating the clinical benefit of combining BRAF inhibitors (BRAFis) with MET inhibitors (METis) to address this mechanism of resistance [49,50].”
BackgroundVan Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01693 · Cited by 103
Molecular targeted therapy of BRAF-mutant colorectal cancer
Ducreux, M., Chamseddine, A., Laurent-Puig, P., Smolenschi, C., Hollebecque, A., Dartigues, P., Samallin, E., Boige, V., Malka, D., & Gelli, M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919856494 · Cited by 100
BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02541 · Cited by 92 · cited 7×
“A phase I clinical trial for mCRC patients with the BRAF V600E mutation combines a Wnti (WNT974) with encorafenib and cetuximab [5].”
BackgroundInfluentialVarga, A., Soria, J.-C., Hollebecque, A., LoRusso, P., Bendell, J., Huang, S.-M. A., Wagle, M.-C., Okrah, K., Liu, L., Murray, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2574 · Cited by 87
BRAF Mutated Colorectal Cancer: New Treatment Approaches
Molina‐Cerrillo, J., Román, M. S., Pozas, J., Alonso‐Gordoa, T., Pozas, M., Conde, E., Cancio-Suárez, M. R., Grande, E., García‐Bermejo, L., & Carrato, A. (2020) · Cancers · doi:10.3390/cancers12061571 · Cited by 87
Inhibitors of BRAF dimers using an allosteric site
Cotto-Rios, X. M., Agianian, B., Gitego, N., Zacharioudakis, E., Giricz, O., Wu, Y., Zou, Y., Verma, A., Poulikakos, P. I., & Gavathiotis, E. (2020) · Nature Communications · doi:10.1038/s41467-020-18123-2 · Cited by 84
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 76
Ros, J., Matito, J., Villacampa, G. J., Comas, R., García, A., Martini, G., Baraibar, I., Gonzalez, N. S., Salvà, F., Martín, Á., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.016 · Cited by 72
Stintzing, S., Heinrich, K., Tougeron, D., Modest, D. P., Schwaner, I., Eucker, J., Pihusch, R., Stauch, M., Kaiser, F., Kahl, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01420 · Cited by 69
Loupakis, F., Intini, R., Cremolini, C., Orlandi, A., Sartore-Bianchi, A., Pietrantonio, F., Pella, N., Spallanzani, A., Dell’Aquila, E., Scartozzi, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.008 · Cited by 69
Middleton, G., Yang, Y., Campbell, C. D., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3579 · Cited by 63
Bottos, A., Martini, M., Di Nicolantonio, F., Comunanza, V., Maione, F., Minassi, A., Appendino, G., Bussolino, F., & Bardelli, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105026109 · Cited by 60
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyla, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K. D., Hughes, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 52
BRAF inhibitors: the current and the future
Zhang, W. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.015 · Cited by 50
CXCR4 overexpression is correlated with poor prognosis in colorectal cancer
Xu, C., Zheng, L., Li, D., Chen, G., Gu, J., Chen, J., & Yao, Q. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.04.050 · Cited by 45
Corcoran, R. B., Giannakis, M., Allen, J. N., Chen, J. Y., Pelka, K., Chao, S. X., Meyerhardt, J. A., Enzinger, A. C., Enzinger, P. C., McCleary, N. J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.041 · Cited by 44
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition
Comunanza, V., Corà, D., Orso, F., Consonni, F. M., Middonti, E., Nicolantonio, F. D., Buzdin, A. A., Sica, A., Médico, E., Sangiolo, D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505774 · Cited by 40
Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39 · cited 1×
“…is essential for prostaglandin synthesis, so using a COX-2 inhibitor in combination with BRAF inhibitors (BRAFis) and/or EGFR inhibitors (EGFRis) is an interesting therapeutic strategy that has already shown longer-lasting suppression of tumor growth in patient-derived tumor xenograft models [67].”
BackgroundKoumaki, K., Kontogianni, G., Kosmidou, V., Pahitsa, F., Kritsi, E., Zervou, M., Chatziioannou, A., Souliotis, V. L., Papadodima, O., & Pintzas, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166061 · Cited by 36 · cited 1×
“In a phase I/II trial evaluating the paradox breaker PLX8394, an objective response rate (ORR) of 22% was achieved in a population of 45 patients with BRAF mutations or fusions [55].”
BackgroundSessile Serrated Polyps: An Important Route to Colorectal Cancer
Kalady, M. F. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0182 · Cited by 33
Pietrantonio, F., Perrone, F., Biondani, P., Maggi, C., Lampis, A., Bertan, C., Venturini, F., Tondulli, L., Ferrari, D., Ricci, V., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26343 · Cited by 28
Kopetz, S., Grothey, A. F., Yaeger, R. D., Ciardiello, F., Desai, J., Kim, T. W., Maughan, T., Cutsem, E. V., Wasan, H. S., Yoshino, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3619 · Cited by 26
Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Grothey, A. F., Cutsem, E. V., Wasan, H. S., Yaeger, R. D., Yoshino, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3513 · Cited by 25
Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients
Ottaiano, A., Scala, S., Normanno, N., Botti, G., Tatangelo, F., Mauro, A. D., Capozzi, M., Facchini, S., Tafuto, S., & Nasti, G. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000828 · Cited by 21
Kopetz, S., Murphy, D. A., Pu, J., Yaeger, R. D., Ciardiello, F., Desai, J., Cutsem, E. V., Wasan, H. S., Yoshino, T., Alkuzweny, B., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.454 · Cited by 19
Quintanilha, J. C. F., Graf, R. P., & Oxnard, G. R. (2023) · The Oncologist · doi:10.1093/oncolo/oyac265 · Cited by 19
Punt, C. J. A., Bond, M. J. G., Bolhuis, K., Loosveld, O. J. L., Helgason, H. H., de Groot, J. W., Hendriks, M. P., Kerver, E. D., Liem, M. S. L., Rijken, A. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.17_suppl.lba3506 · Cited by 14
Tabernero, J. M., Yoshino, T., Kim, T. W., Yaeger, R., Desai, J., Wasan, H. S., Cutsem, E. V., Ciardiello, F., Maughan, T., Eng, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.022 · Cited by 14
Ros, J., & Élez, E. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.026 · Cited by 7
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“This type of targeted therapy is only effective in the absence of mutations in , HER2-positive) ) for CRC with BRAF-V600E mutation, used in combination with EGFR inhibitor cetuximab (Figure 2) [14,34].”
Obesity-Associated Colorectal Cancer
Gonzalez-Gutierrez, L., Motiño, O., Barriuso, D., de la Puente-Aldea, J., Alvarez-Frutos, L., Kroemer, G., Palacios, R., & Senovilla, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168836 · Cited by 60
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 30
Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine
Dosunmu, G. T., & Shergill, A. P. (2024) · Genes · doi:10.3390/genes15050538 · Cited by 21
WHO Classification of Tumours: evolution of a global resource in the molecular era
Hodge, J. C., Netto, G. J., Rekhi, B., Cooper, W. A., Eden, M., Field, A. S., Goh, V., Kench, J. G., Khoury, J. D., Leite, K. R. M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00709-5 · Cited by 16
Metadata
- Authors
- Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., Martínez-Delfrade, Í., Morón, B., de Frutos, B., & Ferreiro, M. R.
- Affiliations
- Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
- Hospital Universitario Ramón y Cajal (ES)
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-10-31
- Volume
- 15
- Issue
- 21
- Pages
- 5243
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10649848
- OpenAlex
- W4388041706
- Cited by
- 21
- References
- 74
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- BRAF inhibitors, metastatic colorectal cancer, BRAF mutation, drug resistance mechanisms, VEGF inhibitors, chemotherapy, immunotherapy, microsatellite instability, targeted therapy, resistance reversal strategies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
